341 related articles for article (PubMed ID: 23359684)
1. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Zhao S; Choi M; Overton JD; Bellone S; Roque DM; Cocco E; Guzzo F; English DP; Varughese J; Gasparrini S; Bortolomai I; Buza N; Hui P; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Carrara L; Pecorelli S; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Stiegler AL; Mane S; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2013 Feb; 110(8):2916-21. PubMed ID: 23359684
[TBL] [Abstract][Full Text] [Related]
2. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
4. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.
Jones NL; Xiu J; Reddy SK; Burke WM; Tergas AI; Wright JD; Hou JY
Gynecol Oncol; 2015 Sep; 138(3):620-6. PubMed ID: 26123645
[TBL] [Abstract][Full Text] [Related]
6. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas.
Moukarzel LA; Ferrando L; Da Cruz Paula A; Brown DN; Geyer FC; Pareja F; Piscuoglio S; Papanastasiou AD; Fusco N; Marchiò C; Abu-Rustum NR; Murali R; Brogi E; Wen HY; Norton L; Soslow RA; Vincent-Salomon A; Reis-Filho JS; Weigelt B
Mol Oncol; 2021 Apr; 15(4):1024-1039. PubMed ID: 33021035
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
8. Integrated Molecular Characterization of Uterine Carcinosarcoma.
Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
[TBL] [Abstract][Full Text] [Related]
9. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Hayes MP; Douglas W; Ellenson LH
Gynecol Oncol; 2009 Jun; 113(3):370-3. PubMed ID: 19272638
[TBL] [Abstract][Full Text] [Related]
11. Germline mutations of the DNA repair pathways in uterine serous carcinoma.
Frimer M; Levano KS; Rodriguez-Gabin A; Wang Y; Goldberg GL; Horwitz SB; Hou JY
Gynecol Oncol; 2016 Apr; 141(1):101-7. PubMed ID: 27016235
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; Zhang S; ; Lozy F; Sgroi DC; Vidal Bel A; Matias-Guiu X; Broaddus RR; Lu KH; Levine DA; Mutch DG; Goodfellow PJ; Salvesen HB; Mullikin JC; Bell DW
Cancer; 2017 Sep; 123(17):3261-3268. PubMed ID: 28485815
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
14. The genetic landscape of endometrial clear cell carcinomas.
DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
[TBL] [Abstract][Full Text] [Related]
15. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
[TBL] [Abstract][Full Text] [Related]
16. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.
Le Gallo M; O'Hara AJ; Rudd ML; Urick ME; Hansen NF; O'Neil NJ; Price JC; Zhang S; England BM; Godwin AK; Sgroi DC; ; Hieter P; Mullikin JC; Merino MJ; Bell DW
Nat Genet; 2012 Dec; 44(12):1310-5. PubMed ID: 23104009
[TBL] [Abstract][Full Text] [Related]
17. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities.
Crane E; Naumann W; Tait D; Higgins R; Herzog T; Brown J
Int J Gynecol Cancer; 2020 Apr; 30(4):480-484. PubMed ID: 32114514
[TBL] [Abstract][Full Text] [Related]
18. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
19. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
20. Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
